Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00061620 · ClinicalTrials.gov registry record · Phase 1

Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies

A Phase 1 study of Hematologic Malignancies, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 1
Development phase
19
Enrollment target
1
Study location

NCT00061620: Completed Phase 1 study of Hematologic Malignancies, sponsored by M.D. Anderson Cancer Center.

NCT00061620 is a Phase 1 study of Hematologic Malignancies that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 19 participants, below the 2,712-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00061620, a Phase 1 study of Hematologic Malignancies, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
19 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to find the highest dose of Tezacitabine (FMdC) which can be safely given as a continuous infusion by vein to patients with hematologic malignancies. The general safety and effectiveness of this drug will also be studied.

Primary Outcome

MTD determination made from dose level without a dose-limiting toxicity (DLT)

Conditions Studied

Hematologic Malignancies

Interventions

  • DRUG Tezacitabine (FMdC)

Study Locations (1)

Texas

  • UT MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2001-09-06
Est. Completion 2004-02-12
Phase Phase 1
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT00061620 record still lists

NCT00061620 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 2,712-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which Tezacitabine (FMdC) is the first listed.

NCT00061620 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00061620 about?

NCT00061620 is a clinical study titled "Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies". The goal of this clinical research study is to find the highest dose of Tezacitabine (FMdC) which can be safely given as a continuous infusion by vein to patients with hematologic malignancies. The general safety and effectiveness of this drug will also be studied.

What is the current status of trial NCT00061620?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2001-09-06. Estimated completion is 2004-02-12.

What conditions does trial NCT00061620 study?

This clinical trial studies the following conditions: Hematologic Malignancies.

What interventions are being tested in trial NCT00061620?

The interventions under investigation include: Tezacitabine (FMdC) (DRUG).

Who is sponsoring clinical trial NCT00061620?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00061620 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hematologic Malignancies

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00061620's enrollment target sits among peer trials

19 42nd of 45 higher than 4 of 45 other Hematologic Malignancies trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hematologic Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03207464 · 19 participants · Phase 1

    Molecular Imaging of NET Using [C-11]MRB-PET in MS

  • NCT04318717 · 19 participants · Phase 2

    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  • NCT05103904 · 19 participants · Phase 2

    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  • NCT05607407 · 19 participants · Phase 2

    Methimazole in Patients With Progressive Glioblastoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT00061620, the US trial registry maintained by the National Library of Medicine. NCT00061620 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.